Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 4
2006 2
2007 1
2008 2
2009 1
2012 4
2013 3
2014 4
2015 5
2016 7
2017 3
2018 3
2019 2
2020 1
2022 3
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Results by year
Filters applied: . Clear all
Page 1
First-in-human uPAR PET: Imaging of Cancer Aggressiveness.
Persson M, Skovgaard D, Brandt-Larsen M, Christensen C, Madsen J, Nielsen CH, Thurison T, Klausen TL, Holm S, Loft A, Berthelsen AK, Ploug M, Pappot H, Brasso K, Kroman N, Højgaard L, Kjaer A. Persson M, et al. Among authors: klausen tl. Theranostics. 2015 Sep 13;5(12):1303-16. doi: 10.7150/thno.12956. eCollection 2015. Theranostics. 2015. PMID: 26516369 Free PMC article. Clinical Trial.
Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.
Svane MS, Johannesen HH, Hansen AE, Martinussen C, Bojsen-Møller KN, Hansen ML, Deacon CF, Keller SH, Klausen TL, Loft A, Kjaer A, Löfgren J, Madsbad S, Holst JJ, Wewer Albrechtsen NJ. Svane MS, et al. Among authors: klausen tl. Int J Obes (Lond). 2022 Nov;46(11):2058-2062. doi: 10.1038/s41366-022-01207-y. Epub 2022 Aug 18. Int J Obes (Lond). 2022. PMID: 35982119
First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using 18F-labeled Active-Site Inhibited Factor VII (18F-ASIS): Potential as Companion Diagnostic.
Loft M, Christensen C, Clausen MM, Carlsen EA, Hansen CP, Kroman N, Langer SW, Høgdall C, Madsen J, Gillings N, Nielsen CH, Klausen TL, Holm S, Loft A, Berthelsen AK, Kjaer A. Loft M, et al. Among authors: klausen tl. J Nucl Med. 2022 Dec;63(12):1871-1879. doi: 10.2967/jnumed.122.264068. Epub 2022 May 19. J Nucl Med. 2022. PMID: 35589407 Clinical Trial.
First-in-Human Study of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET for Integrin αvβ3 Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability.
Clausen MM, Carlsen EA, Christensen C, Madsen J, Brandt-Larsen M, Klausen TL, Holm S, Loft A, Berthelsen AK, Kroman N, Knigge U, Kjaer A. Clausen MM, et al. Among authors: klausen tl. Diagnostics (Basel). 2022 Mar 30;12(4):851. doi: 10.3390/diagnostics12040851. Diagnostics (Basel). 2022. PMID: 35453899 Free PMC article.
Reply to: Adequate use of radioactive seed localisation. Where we are?
Hassing CMS, Tvedskov TF, Kroman N, Klausen TL, Drejøe JB, Tvedskov JF, Lambine TL, Kledal H, Lelkaitis G, Langhans L. Hassing CMS, et al. Among authors: klausen tl. Eur J Surg Oncol. 2018 Oct;44(10):1667. doi: 10.1016/j.ejso.2018.06.018. Epub 2018 Aug 16. Eur J Surg Oncol. 2018. PMID: 30170882 No abstract available.
Radioactive seed localisation of non-palpable lymph nodes - A feasibility study.
Hassing CMS, Tvedskov TF, Kroman N, Klausen TL, Drejøe JB, Tvedskov JF, Lambine TL, Kledal H, Lelkaitis G, Langhans L. Hassing CMS, et al. Among authors: klausen tl. Eur J Surg Oncol. 2018 May;44(5):725-730. doi: 10.1016/j.ejso.2018.02.211. Epub 2018 Mar 6. Eur J Surg Oncol. 2018. PMID: 29545086
35 results